Immutrin

Cambridge, United Kingdom

Immutrin is a biotech developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.

$87.1M raised

Mar 2026

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Immutrin raised?

Immutrin has raised $87.1M in total funding. The most recent round was Series A. The last funding was announced in March 2026.

Who are Immutrin's investors?

Immutrin's investors include Qiming Venture Partners, Parkwalk Advisors, SR One, Frazier Life Sciences, Cambridge Innovation Capital.

Where is Immutrin headquartered?

Immutrin is headquartered in Cambridge, United Kingdom.

What does Immutrin do?

Immutrin is a biotech developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.

What stage is Immutrin at?

Immutrin is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 24, 2026.

MLA

"Immutrin — Funding & Investors." VCBacked, March 24, 2026, https://www.vcbacked.co/company/immutrin. Accessed July 2, 2026.

APA

VCBacked. (2026). Immutrin — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/immutrin

Wikipedia (cite web)

{{cite web |title=Immutrin — Funding & Investors |url=https://www.vcbacked.co/company/immutrin |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 24, 2026.